07:25 AM EDT, 08/14/2026 (MT Newswires) -- (Updates with the Valneva stock movement in the headline and first paragraph.)

Valneva (VALN) shares rose more than 27% in premarket activity Friday after the company and

Pfizer ( PFE ) said that the European Medicines Agency validated their marketing authorization application for their Lyme disease vaccine candidate, starting the regulatory review process.

The Lyme disease vaccine application is based on efficacy of more than 70% observed in a phase 3 trial, said the drug companies. The vaccine was well tolerated in the trial, with no safety concerns identified.

Lyme disease is transmitted to humans through tick bites, and there is no vaccine on the market, said Pfizer ( PFE ) and Valneva.